Drug makers Tercica Inc. and Genentech Inc. said Tuesday they asked a federal court to block Insmed Inc. from bringing its SomatoKine growth therapy to market ahead of a pending patent infringement lawsuit. Insmed and the Tercica-Genentech team are both awaiting approval from the Food and Drug Administration for drugs that treat extreme short stature caused by a rare genetic hormone deficiency. The agency has granted an accelerated priority review of both therapies, with a ruling expected on SomatoKine by July 3 and on Tercica's Increlex by Aug. 31.

Posted by GEN-ERIC at 12:13:13 am into the following categories: In The News

---

http://gen-eric.com/patents/htsrv/trackback.php/250

Name:

Email: (not displayed on this site)

Site/Url:

Comment text:

Allowed XHTML tags: <p, ul, ol, li, dl, dt, dd, address, blockquote, ins, del, a, span, bdo, br, em, strong, dfn, code, samp, kdb, var, cite, abbr, acronym, q, sub, sup, tt, i, b, big, small>

URLs, email, AIM and ICQs will be converted automatically.

Options:
Auto-BR (Line breaks become <br />)
Remember me (Set cookies for name, email & url)